Page 15 - Nifty

Indian equity returns likely muted for remainder of the year, says Nomura

The Japan-based brokerage said the surge in retail flows into domestic mutual funds over the years has been driven by structural factors like under-allocation to equities

Markets catch their breath after record highs; Sensex closes at 79,925

Sharp rebound from election-result day lows is being driven by hopes of policy continuity, foreign portfolio investors (FPIs) turning net buyers again, and strong macroeconomic numbers

Maruti drives mkt euphoria: Nifty hits fresh high, Sensex up over 300 pts

Indian equities have largely been on an upward trajectory following the general election results amidst hopes of policy continuity, earnings stability, and stable macroeconomic numbers

Results preview: India Inc's Q1 FY25 show likely to remain muted

Top line, bottom line growth may be at multi-quarter low

Rebound from election-result day setback; Nifty up 11% in one month

Sensex has added nearly 10,000 points over the past one month

HDFC Bank share price hit all time high; up 2.18% from previous day's close

Analysts expect more upside in the run up to August rebalance of MSCI index weightage

Markets log best monthly gains since Dec amid optimism around new govt

The gains come amid the background of strong economic data and optimism around the functioning of the new government

Banking stocks propel Sensex past 78,000, Nifty50 gains 184 points

Sustained foreign helps indices log best day in over than two weeks

Sun Pharma inks MoU with Takeda to introduce gastrointestinal drug in India

Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India. The company has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in strengths of 10 and 20 mg in India, the Mumbai-based drug major said in a statement. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. "Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda," Sun Pharma CEO - India Business Kirti Ganorkar said. The partnership demonstrates the company's commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders, he added. Gastroesophageal Reflux Disease (GERD) is

Sebi plans tweaks in derivative trading rules to curtail options trading

The new rules could include higher margins for options contracts and more detailed disclosures

Street signs: Nifty hits a speed hump, MF industry on tax tightrope, more

The mutual fund (MF) industry is concerned that the upcoming Union Budget may bring another tax blow

Modi 3.0? Exit polls trigger the best day for indices in three years

Sensex, Nifty jump over 3% each; investor wealth surges Rs 14 trn; FPIs pump in Rs 6.9K cr

Nifty Bank index races past 50,000 mark in post-election euphoria

Public-sector undertaking (PSU) banks were among biggest gainers on Monday, leading to a 8.4 per cent rise in the Nifty PSU Bank index, a index of only government-owned lenders

Sensex may target 80,000 levels post exit poll data. Check key levels here

However, in case, the BSE Sensex is unable to break past the 76,275 level, we may enter a consolidation range, wherein the support at 72,240 becomes a crucial level.

Nifty to hit 26,500 in 18 months? Why investors need multi-cap strategy

Emkay Investment Managers predict Nifty to reach 26,500 by 2025, citing factors like 15% earnings growth, positive election outcome & sectoral focus on BFSI, PSUs, and green energy

Nifty can jump 10% in a week if NDA crosses 400-seat tally in Lok Sabha polls

With barely a fortnight remaining for the outcome of the Lok Sabha polls, markets seem to be a bit nervous. Puneet Wadhwa caught up with RAHUL ARORA, CEO for Institutional Equities at Nirmal Bang

Rupee appreciates 4 paise to 83.47 against US dollar in early trade

The rupee was trading in a narrow range and appreciated 4 paise to 83.47 against the US dollar in early trade on Wednesday, tracking a positive trend in domestic equities. However, sustained foreign fund outflows weighed on the local unit and restricted the up move. Forex traders said with foreign investors buying US dollars and the Reserve Bank of India (RBI) selling the greenback, the USD/INR pair is expected to remain range-bound with a bit of a weakness bias. At the interbank foreign exchange market the local unit moved in a narrow range. It opened at 83.49 against the American currency and touched 83.47 in initial trade, registering a rise of 4 paise from its previous close. On Tuesday, the rupee closed at 83.51 against the American currency. Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, was at 104.93, lower by 0.07 per cent. Brent crude futures, the global oil benchmark, rose 0.69 per cent to USD 82.95 per barrel. Des

Markets log biggest drop in 4 months; Sensex ends 1,062 points lower

The index finished below its 100-day moving average (DMA), seen as a critical support, for the first time since November 13, 2023

Nifty ends flat for 12th time in history, session closes at 22,302.5

The last time this happened was on March 31, 2017, when Nifty closed at 9,173.75

NSE investors may face further delays for its initial public offering

According to industry players, one of the key requirements for approving NSE's IPO is for it to remain free from any tech-glitch for a year